- ISIN
- CA22587M1068
- CUSIP
- 22587M106
- Sector
- Healthcare
Highlights
- Market Cap
- $280.46M
- Enterprise Value
- $829.27M
- EPS (TTM)
- -$0.39
- Total Revenue (TTM)
- $641.80M
- Gross Profit (TTM)
- $311.73M
- EBITDA (TTM)
- $108.21M
- Year Range
- $0.44 - $2.30
- Target Price
- $5.50
- ROA (TTM)
- -11.36%
- ROE (TTM)
- -40.52%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CRLBF Performance Chart
Cresco Labs Inc (CRLBF) is down 37.4% since the beginning of the year. At $1 per share, CRLBF is trading 66.5% below its 52-week high of $2. Investors who bought $1,000 worth of CRLBF shares 5 years ago would now be looking at an investment worth $71.
Loading charts...
Returns By Period
Cresco Labs Inc (CRLBF) has returned -37.40% so far this year and 78.41% over the past 12 months.
Cresco Labs Inc
- 1D
- -4.94%
- 1M
- -10.48%
- YTD
- -37.40%
- 6M
- -34.36%
- 1Y
- 78.41%
- 3Y*
- -21.63%
- 5Y*
- -41.03%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
CRLBF Monthly Returns History
Based on dividend-adjusted daily data since Dec 3, 2018, CRLBF's average daily return is +0.05%, while the average monthly return is +0.95%. At this rate, an investment would double in approximately 6.1 years.
Historically, 44% of months were positive and 56% were negative. The best month was Aug 2025 with a return of +154.0%, while the worst month was Dec 2022 at -46.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, CRLBF closed higher 45% of trading days. The best single day was Dec 12, 2025 with a return of +83.6%, while the worst single day was Dec 18, 2025 at -37.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -15.45% | -4.81% | -12.12% | 25.29% | -15.89% | -16.01% | -37.40% | ||||||
| 2025 | 1.78% | -5.21% | -17.76% | 34.48% | -38.35% | -14.54% | 15.51% | 153.96% | -12.14% | -8.61% | -36.81% | 60.87% | 34.61% |
| 2024 | 50.46% | -15.20% | 19.65% | 19.81% | -22.98% | -17.28% | 1.27% | -2.04% | 6.55% | -12.57% | -19.18% | -22.57% | -32.61% |
| 2023 | 2.78% | -6.49% | -10.40% | 0.65% | 8.97% | -11.47% | 8.11% | -2.89% | 28.48% | -36.95% | 32.93% | -20.32% | -24.68% |
| 2022 | -7.63% | 13.46% | -14.09% | -26.73% | -13.41% | -34.38% | 36.64% | 21.78% | -34.86% | 21.40% | 1.82% | -46.27% | -73.01% |
| 2021 | 19.51% | 22.37% | -13.36% | 4.00% | -5.77% | -6.94% | -6.59% | -7.03% | -6.26% | -15.95% | 4.75% | -18.36% | -32.39% |
Benchmark Metrics
Cresco Labs Inc has an annualized alpha of -2.69%, beta of 1.03, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since December 03, 2018.
- This stock participated in 142.55% of S&P 500 Index downside but only 14.42% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -2.69%
- Beta
- 1.03
- R²
- 0.05
- Upside Capture
- 14.42%
- Downside Capture
- 142.55%
Return for Risk
Risk / Return Rank
CRLBF ranks 68 for risk / return — better than 68% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Cresco Labs Inc (CRLBF) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CRLBF | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.50 | ||
| Sortino ratioReturn per unit of downside risk | -0.76 | ||
| Omega ratioGain probability vs. loss probability | 1.23 | 1.37 | -0.13 |
| Calmar ratioReturn relative to maximum drawdown | 1.32 | 2.78 | -1.47 |
| Martin ratioReturn relative to average drawdown | 2.10 | 12.44 | -10.34 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cresco Labs Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cresco Labs Inc was 97.45%, occurring on Jun 20, 2025. The portfolio has not yet recovered.
The current Cresco Labs Inc drawdown is 95.44%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -97.45%Jun 2025 | 4y 4mo | — | 5y 4moFeb 2021 - now |
COVID crash2020 | -84.50%Mar 2020 | 10mo 24d | 10mo 3d | 1y 8moApr 2019 - Jan 2021 |
Rate-hike selloffLate 2018 | -18.10%Dec 2018 | 1d | 7d | 8dDec 2018 - Dec 2018 |
2021 correction2021 | -17.55%Jan 2021 | 5d | 8d | 13dJan 2021 - Feb 2021 |
Rate-hike selloffLate 2018 | -16.75%Dec 2018 | 5d | 9d | 14dDec 2018 - Dec 2018 |
Drawdown Indicators
| CRLBF | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.45% | -56.78% | -40.67% |
Max Drawdown (1Y)Largest decline over 1 year | -59.81% | -9.10% | -50.71% |
Max Drawdown (3Y)Largest decline over 3 years | -83.90% | -18.90% | -65.00% |
Max Drawdown (5Y)Largest decline over 5 years | -96.28% | -25.43% | -70.85% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -95.44% | -1.80% | -93.64% |
Average DrawdownAverage peak-to-trough decline | -67.74% | -10.71% | -57.03% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 37.45% | 2.03% | +35.42% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cresco Labs Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cresco Labs Inc is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CRLBF relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, CRLBF has a P/S ratio of 0.4. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CRLBF in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, CRLBF has a P/B value of 0.8. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CRLBF
Add Cresco Labs Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CRLBF